CVR 30082346Public limited company (A/S)Fremstilling af farmaceutiske præparater (212000)HørsholmFounded 4 Dec 2006
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about REPONEX PHARMACEUTICALS A/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
2
CVR, Aug 2026
0 (0%) over 12 months
Revenue
0
DKK, group, annual report 2025
Result
-6.6M
DKK, group, annual report 2025
Equity
4.6M
DKK, group, annual report 2025
Pharma Equity Group A/SCVR 26791413, 100% of capital and votes
Operating company
Dandex estimate: 2 employees registered in 2026Christian Henrik Tangesince 19 Dec 2025
Owners of 5% or more. CVR registers shares in bands, not exact figures.
CVR 26791413100% of capital and votesnotified 14 Aug 2023since 24 Mar 2023
CVR 255228265% to under 10% of capital and votesnotified 14 Aug 202313 Mar 2019 to 24 Mar 2023
CVR 288640005% to under 10% of capital and votesnotified 5 May 20188 Dec 2014 to 7 Jul 2019
CVR 2991468010% to under 15% of capital and votesnotified 14 Aug 20235 Feb 2018 to 24 Mar 2023
CVR 333619985% to under 10% of capital and votes30 Nov 2015 to 28 Sep 2016
CVR 162589035% to under 10% of capital and votes12 Nov 2014 to 7 Jul 2015
CVR 308102795% to under 10% of capital and votes2 Jul 2015 to 29 Nov 2015
CVR 335900835% to under 10% of capital and votes12 Nov 2014 to 28 Apr 2016
CVR 3520608620% to under 25% of capital and votesnotified 14 Aug 202312 Nov 2014 to 24 Mar 2023
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
Aug 2026, monthly: 2 employees, 1 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Jan 2017 | Feb 2017 | Mar 2017 | Apr 2017 | May 2017 | Jun 2017 | Jul 2017 | Aug 2017 | Sep 2017 | Oct 2017 | Nov 2017 | Dec 2017 | Jan 2018 | Feb 2018 | Mar 2018 | Apr 2018 | May 2018 | Jun 2018 | Jul 2018 | Aug 2018 | Sep 2018 | Oct 2018 | Nov 2018 | Dec 2018 | Jan 2019 | Feb 2019 | Mar 2019 | Apr 2019 | May 2019 | Jun 2019 | Jul 2019 | Aug 2019 | Sep 2019 | Oct 2019 | Nov 2019 | Dec 2019 | Jan 2020 | Feb 2020 | Mar 2020 | Apr 2020 | May 2020 | Jun 2020 | Jul 2020 | Aug 2020 | Sep 2020 | Oct 2020 | Nov 2020 | Dec 2020 | Jan 2021 | Feb 2021 | Mar 2021 | Apr 2021 | May 2021 | Jun 2021 | Jul 2021 | Aug 2021 | Sep 2021 | Oct 2021 | Nov 2021 | Dec 2021 | Jan 2022 | Feb 2022 | Mar 2022 | Apr 2022 | May 2022 | Jun 2022 | Jul 2022 | Aug 2022 | Sep 2022 | Oct 2022 | Nov 2022 | Dec 2022 | Jan 2023 | Feb 2023 | Mar 2023 | Apr 2023 | May 2023 | Jun 2023 | Jul 2023 | Aug 2023 | Sep 2023 | Oct 2023 | Nov 2023 | Dec 2023 | Jan 2024 | Feb 2024 | Mar 2024 | Apr 2024 | May 2024 | Jun 2024 | Jul 2024 | Aug 2024 | Sep 2024 | Oct 2024 | Nov 2024 | Dec 2024 | Jan 2025 | Feb 2025 | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 7 | 7 | 6 | 6 | 6 | 7 | 6 | 5 | 7 | 7 | 6 | 6 | 8 | 6 | 6 | 8 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | 2 |
| FTE | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 4 | 5 | 5 | 5 | 5 | 6 | 5 | 4 | 6 | 5 | 5 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Series | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group. CVR changed its monthly method in Oct 2019: a step there need not be real.
Source: CVR, latest Aug 2026, published 21 Oct 2026.
Group figures (koncern), each year in its report's currency, from the annual reports filed in XBRL.
| Thousands | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | Not reported | 0 | 0 | 0 |
| Gross profit | 0 | Not reported | 0 | 0 | 0 |
| Operating profit | -12,604 | -12,043 | -16,600 | -13,507 | -7,693 |
| Result for the year | -9,883 | -10,210 | -14,346 | -11,943 | -6,570 |
| Equity | 27,371 | 17,379 | 16,757 | -8,785 | 4,645 |
| Total assets | 28,708 | 19,984 | 21,662 | 3,631 | 7,301 |
| Credit metrics (Dandex calculations) | |||||
| EBITDA | Not reportednote 1 | Not reportednote 1 | Not reportednote 1 | Not reportednote 1 | -7,382 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex (investeringer i anlægsaktiver) | 0 | Not reportednote 2 | 73 | 0 | 274note 3 |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions.
Large listed filers report IFRS figures in an ESEF report, for the group where there is one.
How each credit metric is calculated:
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for REPONEX PHARMACEUTICALS A/S:
Have Pro? Sign in.
Amounts in DKK. Cash price is per DKK 1 of nominal capital, which a share split does not move. Implied value is the whole capital after the step at its cash price, not a valuation.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseCashPaid in 12,704,125, cash price 625.00, implied value 531,167,188 | 625.00 | 12,704,125 | 531,167,188 | 849,868 | |
| IncreaseCashPaid in 24,999,997, cash price 110.00, implied value 91,249,499 | 110.00 | 24,999,997 | 91,249,499 | 829,541 | |
| IncreaseCashPaid in 14,999,996, cash price 220.00, implied value 132,499,004 | 220.00 | 14,999,996 | 132,499,004 | 602,268 | |
| IncreaseBonus issue from reserves | None | None | None | 534,086 | |
| IncreaseCashPaid in 1,449,921, cash price 878.90, implied value 117,352,134 | 878.90 | 1,449,921 | 117,352,134 | 133,522 | |
| IncreaseCashPaid in 4,150,078, cash price 878.90, implied value 115,902,213 | 878.90 | 4,150,078 | 115,902,213 | 131,872 | |
| IncreaseDebt conversionPaid in 1,922,408 | None | 1,922,408 | None | 127,150 | |
| FoundingNot read from the announcement | None | None | None | 125,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Source: CVR, read 19 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 19 Nov 2026.
41 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Ny adresse: Slotsmarken 12, 1. th, 2970 Hørsholm
Direktion:
Fratrådte:
Sebastian Bo Jakobsen, (adm. dir), den 19.12.2025.
Tiltrådte:
Christian Henrik Tange, (adm. dir), den 19.12.2025.
Revision:
Fratrådte:
BDO Holding VII, statsautoriseret revisionsaktieselskab, den 12.08.2025.
Tiltrådte:
CVR-NR. 45719375 BDO 2025 Statsautoriseret Revisionspartnerselskab, Havneholmen 29, 1561 København V, den 12.08.2025.
Direktion:
Fratrådte:
Thomas Kaas Selsø, (adm. dir), den 01.04.2025.
Tiltrådte:
Sebastian Bo Jakobsen, (adm. dir), den 01.04.2025.
Revision:
Fratrådte:
GRANT THORNTON,STATSAUTORISERET REVISIONSPARTNERSELSKAB, den 27.04.2023.
Tiltrådte:
CVR-NR. 20222670 BDO STATSAUTORISERET REVISIONSAKTIESELSKAB, Havneholmen 29, 1561 København V, den 27.04.2023.
Bestyrelse:
Fratrådte:
Peter Mørch Eriksen, den 15.06.2023.
Direktion:
Fratrådte:
CEO Søren Nielsen, (adm. dir), den 14.06.2023, Thomas Kaas Selsø, den 14.06.2023.
Tiltrådte:
Thomas Kaas Selsø, (adm. dir), den 14.06.2023.
Bestyrelse:
Fratrådte:
Lisbeth Thyregod, den 27.04.2023, Mette Zacho, den 27.04.2023.
Vedtægter ændret: 31.03.2023
Bestyrelse:
Fratrådte:
CEO Søren Nielsen, den 31.03.2023.
Tiltrådte:
Peter Mørch Eriksen, den 31.03.2023, Mette Zacho, den 31.03.2023.
Ny adresse: Slotsmarken 18, 2. th, 2970 Hørsholm
Vedtægter ændret: 10.02.2023
Kapitalforhøjelsen er besluttet den 10.02.2023.
kr. 20.326,60, indbetalt kontant, kurs 62.500,00.
Kapitalen udgør herefter kr. 849.867,50.
Bestyrelse:
Fratrådte:
CEO Søren Nielsen, (formand), den 11.10.2022, Christian Vinding Thomsen, den 11.10.2022.
Tiltrådte:
CEO Søren Nielsen, den 11.10.2022, Christian Vinding Thomsen, (formand), den 11.10.2022.
Direktion:
Tiltrådte:
CEO Søren Nielsen, (adm. dir), den 11.10.2022.
Direktion:
Fratrådte:
Klaus Snej Jensen, (adm. dir), den 11.10.2022.
Bestyrelse:
Fratrådte:
Katrine Hoff Schlichtkrull, den 14.10.2021.
Vedtægter ændret: 22.06.2021
Bestyrelse:
Fratrådte:
Troels Peter Troelsen, den 22.06.2021.
Tiltrådte:
Katrine Hoff Schlichtkrull, den 22.06.2021, Christian Vinding Thomsen, den 22.06.2021, Troels Peter Troelsen, (næstformand), den 22.06.2021.
Selskabet tegnes af direktøren og formanden for bestyrelsen i forening eller af den samlede bestyrelse.
Vedtægter ændret: 18.06.2021
Kapitalforhøjelsen er besluttet den 18.06.2021.
kr. 227.272,70, indbetalt kontant, kurs 11.000,00.
Kapitalen udgør herefter kr. 829.540,90.
Direktion:
Fratrådte:
Torsten Bjørn, den 01.03.2021.
Tiltrådte:
Klaus Snej Jensen, (adm. dir), den 01.03.2021.
Vedtægter ændret: 27.08.2020
Vedtægter ændret: 17.06.2019
Bestyrelse:
Fratrådte:
Henrik Bulskov, den 17.06.2019, Troels Peter Troelsen, (formand), den 17.06.2019.
Tiltrådte:
CEO Søren Nielsen, (formand), den 17.06.2019, Troels Peter Troelsen, den 17.06.2019.
Vedtægter ændret: 21.01.2019
Kapitalforhøjelsen er besluttet den 21.01.2019.
kr. 68.181,80, indbetalt kontant, kurs 22.000,00.
Kapitalen udgør herefter kr. 602.268,20.
Virksomheden er omdannet til et aktieselskab med CVR-NR. 30082346
Vedtægter ændret: 14.05.2018
Nyt navn: REPONEX PHARMACEUTICALS A/S
Nye binavne: Heslet Pharma A/S, TRIFOILIUM A/S
Slettede binavne: TRIFOILIUM ApS, HESLET PHARMA ApS
Kapitalforhøjelsen er besluttet den 14.05.2018.
kr. 400.564,80, indbetalt ved overførte reserver / overskud, kurs 100,00.
Kapitalen udgør herefter kr. 534.086,40.
Bestyrelse:
Tiltrådte:
Charlotte Pahl, den 14.05.2018.
Vedtægter ændret: 01.11.2016
Kapitalforhøjelsen er besluttet den 01.11.2016.
kr. 1.649,70, indbetalt kontant, kurs 87.890,00.
Kapitalen udgør herefter kr. 133.521,60.
Vedtægter ændret: 29.09.2016
Kapitalforhøjelsen er besluttet den 29.09.2016.
kr. 4.721,90, indbetalt kontant, kurs 87.890,00.
Kapitalen udgør herefter kr. 131.871,90.
Bestyrelse:
Fratrådte:
Troels Peter Troelsen, den 21.06.2016.
Tiltrådte:
Erik Lennard Vitting Skovbjerg, den 21.06.2016, Troels Peter Troelsen (formand), den 21.06.2016.
Direktion:
Fratrådte:
Henrik Lasse Lindblad (adm. dir), den 19.04.2016.
Tiltrådte:
Torsten Bjørn, den 19.04.2016.
CVR-nummer
30082346.
NAVN:
REPONEX PHARMACEUTICALS ApS.
Adresse: Slotsmarken 12, 1. th., 2970 Hørsholm.
Kommune: Hørsholm.
Vedtægter ændret: 17.03.2015
Bestyrelse:
Tiltrådte:
Henrik Bulskov, den 17.03.2015, Jacob Rosenberg (formand), den 17.03.2015, Troels Peter Troelsen, den 17.03.2015.
Selskabet tegnes af direktøren og et bestyrelsesmedlem i forening eller af formanden forbestyrelsen og et andet bestyrelsesmedlem i forening eller af den samlede bestyrelse..
Vedtægter ændret:
12.11.2014.
Nyt navn:
REPONEX PHARMACEUTICALS ApS.
Nye binavne:
HESLET PHARMA ApS, TRIFOILIUM ApS.
Kapitalforhøjelse:
kr. 2.150,00 indbetalt ved konvertering af gæld, kurs 89.414,33.
Kapitalen udgør herefter kr. 127.150,00.
Ny adresse:
Slotsmarken 12, 1. th., 2970 Hørsholm.
Ny kommune:
Hørsholm.
Vedtægter ændret:
17.05.2011.
Nyt navn:
TRIFOILIUM ApS.
Vedtægter ændret:
31.05.2010.
Selskabet tegnes af en direktør.
Direktion:
Udtrådt af direktionen:
Michael Secher, den 02.02.2010.
Indtrådt i direktionen:
Henrik Lasse Lindblad (adm. dir), den 02.02.2010.
Direktion:
Udtrådt af direktionen:
Jon Steffen Therkildsen, den 31.12.2008.
Indtrådt i direktionen:
Direktør Michael Secher, den 31.12.2008.
Revision:
Udtrådt af revisionen:
RevisionsFirmaet Edelbo og Lund-Larsen I/S, den 31.12.2008.
Indtrådt i revisionen:
KRESTEN FOGED STATSAUTORISERET REVISIONSAKTIESELSKAB, Frederiksgade 1, 1265 København K, den 31.12.2008.
Revision:
Udtrådt af revisionen:
Lund-Larsen statsautoriserede Revisorer, den 01.10.2007.
Indtrådt i revisionen:
RevisionsFirmaet Edelbo og Lund-Larsen I/S, Frederiksholms Kanal 2, 1., 1220 København K, den 01.10.2007.
Direktion:
Udtrådt af direktionen:
Mikael Thiesen, den 15.05.2007.
Indtrådt i direktionen:
Jon Steffen Therkildsen, den 15.05.2007.
Vedtægter ændret:
13.03.2007.
Ny adresse:
c/o POLINVEST A/S, Kongevejen 153, 2830 Virum.
Ny kommune:
Lyngby-Taarbæk.
Stiftelsesdato:
04.12.2006.
Seneste vedtægtsdato:
04.12.2006.
Kapital:
kr. 125.000,00.
Indbetalingsmåde:
kontant kr. 125.000,00 til kurs 100,00.
Stifter:
CVR-NR. 29837945 POLINVEST A/S, Store Kongensgade 48, 1264 København K, den 04.12.2006.
Direktion:
Mikael Thiesen, den 04.12.2006.
Selskabet tegnes af selskabets direktion. Direktionen vælges på generalforsamlingen for et år ad gangen.
Revision:
Lund-Larsen statsautoriserede Revisorer, 1220 København K, den 04.12.2006.
Første regnskabsår:
04.12.2006 - 31.12.2007.
Regnskabsår:
01.01 - 31.12.
P-number 1012824587Slotsmarken 12, 2970 Hørsholm